BIOTECH

BIOTECH

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment

STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines...

Read more

BIOTECH

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V

The transaction reflects a pre-money equity value of $400 million for AUM Biosciences Transaction is...

Read more

BIOTECH

Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01

Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders...

Read more

BIOTECH

AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) — AUM Biosciences, a global clinical-stage...

Read more

BIOTECH

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology...

Read more